Academic Journal
THU0307 RESPONSE OF BEHÇET’S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE
| العنوان: | THU0307 RESPONSE OF BEHÇET’S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE |
|---|---|
| المؤلفون: | Herrero Morant, A., Atienza Mateo, B., Loricera, J., Calvo del Rio, V., Martín-Varillas, J. L., Graña, J., Espinosa, G., Moriano, C., Pérez Sandoval, T., Martín Martínez, M., Diez, E., García-Armario, M. D., Martínez, E., Castellví, I., Moya Alvarado, P., Sivera, F., Calvo, J., De la Morena, I., Ortiz Sanjuán, F., Román Ivorra, J. A., Pérez Gómez, A., Heredia, S., Olive, A., Prior, Á., Díez, C., Alegre-Sancho, J. J., Ybáñez-García, D., Martínez-Ferrer, Á., Narváez, J., Figueras, I., Turrión, A. I., Romero-Yuste, S., Trénor, P., Ojeda, S., González-Gay, M. Á., Blanco, R. |
| المصدر: | Annals of the Rheumatic Diseases ; volume 79, issue Suppl 1, page 382.2-382 ; ISSN 0003-4967 1468-2060 |
| بيانات النشر: | BMJ |
| سنة النشر: | 2020 |
| الوصف: | Background: Apremilast (APR) has demonstrated efficacy in the treatment of oral and/or genital aphthous ulcers in Behçet´s disease (BD). Combination of APR to other disease-modifying anti-rheumatic drugs (DMARDs) has not been assessed. Objectives: To compare the efficacy and safety of APR in monotherapy or combined with DMARDs in refractory BD. Methods: National multicenter open-label study on 51 BD patients with oral and/or genital ulcers refractory to conventional treatment. Results: We included 51 patients (35 women/16 men), mean age 44.7±13.2 years. Before APR, all patients had received several systemic conventional drugs. The main clinical symptoms for starting APR were oral (n=19) and genital (2) aphthous ulcers or both (30). Excluding corticosteroids, colchicine or NSAIDs, APR was given at standard dose of 30 mg twice daily in monotherapy (n=31), or combined with conventional DMARDs in 16 cases (6 azathioprine, 5 methotrexate, 4 hydroxychloroquine, 4 sulfasalazine, 1 dapsone) or with biologic DMARDs in 4 (2 tocilizumab, 1 adalimumab, 1 infliximab). There were not found statistically significant differences in demographic features, previous therapy, clinical manifestations or reported adverse effects. After a median follow-up of 6 [3-12] months, most of the patients experienced improvement of the orogenital ulcers in both groups (89.8% in the first 2 weeks), without statistically significant differences. (TABLE ) Conclusion: APR leads to a rapid and maintained improvement in most patients with refractory BD orogenital ulcers. APR seems as effective and safe in monotherapy as combined. TABLE: Week 1-2 Week 4 Month 6 Month 12 Month 24 Outcome of oral and/or genital ulcers n, (% ) C n=19 M n=30 C n=19 M n=26 C n=12 M n=17 C n=7 M n=6 C n=1 M n=1 Complete resolution 8 (42.1) 11 (36.7) 12 (63.2) 20 (77) 7 (58.4) 14 (82.4) 3 (42.8) 3 (50) 1 (100) 1 (100) Partial resolution 9 (47.4) 16 (53.4) 7 (36.8) 3 (11.5) 5 (41.6) 2 (11.7) 4 (57.2) 3 (50) 0 0 No response 2 (10.5) 3 (9.9) 0 3 (11.5) 0 1 (5.9) 0 0 0 0 p value ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1136/annrheumdis-2020-eular.6246 |
| الاتاحة: | http://dx.doi.org/10.1136/annrheumdis-2020-eular.6246 https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-eular.6246 |
| رقم الانضمام: | edsbas.84AD7FDF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/annrheumdis-2020-eular.6246 |
|---|